Evaluating biomarkers in advanced follicular lymphoma treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the role of EZH2 aberrations in patients with advanced follicular lymphoma (FL) who have been treated with immunochemotherapy. It utilizes biological samples collected from the FIL_FOLL12 trial, which enrolled 807 patients, to validate the predictive value of EZH2 mutations and guide treatment decisions between different chemotherapy regimens. Additionally, the study will explore novel biomarkers related to FL heterogeneity and establish a network of laboratories in Italy for rapid biomarker analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient enrolled in the FIL\_FOLL12 trial (documented by the signature of the study informed consent);
* Availability of biological samples: bone marrow aspirate, peripheral blood and/or FFPE diagnostic sample (nodal or extranodal);

Exclusion Criteria:

* None

Where it's running

• A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia
  Alessandria, Italy Recruiting
• Nuovo Ospedale degli Infermi, SSD Ematologia
  Biella, Italy Recruiting
• ASST Spedali Civili di Brescia - Ematologia
  Brescia, Italy Recruiting
• Azienda Ospedaliera Universitaria Policlinico - S. Marco, UOC di Ematologia
  Catania, Italy Recruiting
• Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia, Ematologia e terapie cellulari
  Genova, Italy Recruiting
• IRCCS Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" - IRST S.R.L., Ematologia
  Meldola, Italy Recruiting

Study contacts

• Principal investigator: Simone Ferrero, MD — SC Ematologia U - AOU Città della Salute e della Scienza di Torino
• Study coordinator: Uffici Studi FIL
• Email: startup@filinf.it
• Phone: +390131033153

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• MK-1045 and Rituximab in Follicular Lymphoma

  This study tests whether adding MK-1045 to rituximab can help people with follicular lymphoma after standard therapy.

  Recruiting at 38 sites Phase 2/3 Merck Sharp & Dohme LLC · Duarte, California and 37 other locations · NCT07634471

• Mosunetuzumab and Zeprumetostat in Follicular Lymphoma

  This study tests whether a combination of Mosunetuzumab and Zeprumetostat can help adults with follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07555470

• Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma

  This trial tests whether the combination of zanubrutinib, obinutuzumab, and lenalidomide is safe and effective as a chemotherapy-free first treatment for adults with untreated follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07299149

• LY4584180 with rituximab for adults with previously treated B‑cell lymphomas

  This trial will test LY4584180 together with rituximab in adults with previously treated B‑cell lymphomas to see if it is safe, reaches useful levels in the blood, and can help control the disease.

  Recruiting at 21 sites Phase 1 Eli Lilly and Company · Scottsdale, Arizona and 45 other locations · NCT07226843

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.